SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc – ‘10-K’ for 12/31/18 – ‘EX-31.2’

On:  Friday, 3/8/19, at 12:33pm ET   ·   For:  12/31/18   ·   Accession #:  1564590-19-6918   ·   File #:  1-36385

Previous ‘10-K’:  ‘10-K’ on 3/14/18 for 12/31/17   ·   Next:  ‘10-K’ on 3/30/20 for 12/31/19   ·   Latest:  ‘10-K’ on 3/21/24 for 12/31/23   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/08/19  Biolase, Inc                      10-K       12/31/18   86:14M                                    ActiveDisclosure/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.28M 
 2: EX-10.28    Material Contract                                   HTML     93K 
 3: EX-21.1     Subsidiaries List                                   HTML     22K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     26K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     32K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     26K 
15: R1          Document and Entity Information                     HTML     60K 
16: R2          Consolidated Balance Sheets                         HTML    109K 
17: R3          Consolidated Balance Sheets (Parenthetical)         HTML     46K 
18: R4          Consolidated Statements Of Operations And           HTML    108K 
                Comprehensive Loss                                               
19: R5          Consolidated Statements Of Shareholders' Equity     HTML     95K 
20: R6          Consolidated Statements Of Shareholders' Equity     HTML     26K 
                (Parenthetical)                                                  
21: R7          Consolidated Statements Of Cash Flows               HTML    141K 
22: R8          Basis of Presentation                               HTML     43K 
23: R9          Summary of Significant Accounting Policies          HTML    277K 
24: R10         Supplementary Balance Sheet Information             HTML    138K 
25: R11         Intangible Assets and Goodwill                      HTML     66K 
26: R12         Income Taxes                                        HTML    226K 
27: R13         Debt                                                HTML     91K 
28: R14         Commitments and Contingencies                       HTML     47K 
29: R15         Stockholders' Equity                                HTML    418K 
30: R16         Segment Information                                 HTML     49K 
31: R17         Concentrations                                      HTML     89K 
32: R18         Subsequent Events (Unaudited)                       HTML     31K 
33: R19         Schedule II-Consolidated Valuation and Qualifying   HTML    118K 
                Accounts and Reserves                                            
34: R20         Summary of Significant Accounting Policies          HTML    367K 
                (Policies)                                                       
35: R21         Summary of Significant Accounting Policies          HTML    242K 
                (Tables)                                                         
36: R22         Supplementary Balance Sheet Information (Tables)    HTML    144K 
37: R23         Intangible Assets and Goodwill (Tables)             HTML     64K 
38: R24         Income Taxes (Tables)                               HTML    224K 
39: R25         Debt (Tables)                                       HTML     78K 
40: R26         Commitments and Contingencies (Tables)              HTML     36K 
41: R27         Stockholders' Equity (Tables)                       HTML    353K 
42: R28         Segment Information (Tables)                        HTML     47K 
43: R29         Concentrations (Tables)                             HTML     89K 
44: R30         Basis of Presentation - Additional Information      HTML     68K 
                (Detail)                                                         
45: R31         Summary of Significant Accounting Policies -        HTML    100K 
                Additional Information (Detail)                                  
46: R32         Schedule of Reconciliation of Cash, Cash            HTML     36K 
                Equivalents, and Restricted Cash (Detail)                        
47: R33         Estimated Useful Lives of Property, Plant and       HTML     38K 
                Equipment (Detail)                                               
48: R34         Summary of Opening and Closing Balances of          HTML     40K 
                Contract Liabilities (Detail)                                    
49: R35         Summary of Disaggregation of Revenues Related to    HTML     32K 
                Geographic Areas (Detail)                                        
50: R36         Summary of Revenues Disaggregated by Timing of      HTML     33K 
                Goods and Services Transferred (Detail)                          
51: R37         Summary of Sales by End Market (Detail)             HTML     33K 
52: R38         Changes in Initial Product Warranty Accrual and     HTML     40K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
53: R39         Classification of Compensation Expense Associated   HTML     38K 
                with Share-Based Payments (Detail)                               
54: R40         Assumptions Used in Estimating Fair Value of Stock  HTML     33K 
                Options Granted (Detail)                                         
55: R41         Components of Accounts Receivable, Net of           HTML     33K 
                Allowance (Detail)                                               
56: R42         Supplementary Balance Sheet Information -           HTML     42K 
                Additional Information (Detail)                                  
57: R43         Components of Inventory (Detail)                    HTML     35K 
58: R44         Summary of Property, Plant, and Equipment (Detail)  HTML     50K 
59: R45         Components of Accrued Liabilities (Detail)          HTML     49K 
60: R46         Intangible Assets and Goodwill - Additional         HTML     33K 
                Information (Detail)                                             
61: R47         Intangible Assets and Related Accumulated           HTML     52K 
                Amortization (Detail)                                            
62: R48         Summary of Income Tax Current and Deferred          HTML     43K 
                Provision (Detail)                                               
63: R49         Federal Income Tax Provision Compared With          HTML     55K 
                Statutory Rates (Detail)                                         
64: R50         Summary of Net Deferred Tax Assets and Net          HTML     78K 
                Deferred Tax Liabilities (Detail)                                
65: R51         Income Taxes - Additional Information (Detail)      HTML     80K 
66: R52         Summary of Unrecognized Tax Benefits (Detail)       HTML     31K 
67: R53         Debt - Summary of Principal Outstanding and         HTML     32K 
                Unamortized Discount (Detail)                                    
68: R54         Debt - Additional Information (Detail)              HTML    161K 
69: R55         Debt - Summary of Future Minimum Principal          HTML     51K 
                Payments (Detail)                                                
70: R56         Commitments and Contingencies - Additional          HTML     48K 
                Information (Detail)                                             
71: R57         Future Minimum Rental Commitments Under Lease       HTML     35K 
                Agreements (Detail)                                              
72: R58         Stockholders' Equity - Additional Information       HTML    810K 
                (Detail)                                                         
73: R59         Summary of Warrant Activity (Detail)                HTML     54K 
74: R60         Summary of Option Activity (Detail)                 HTML     66K 
75: R61         Options Outstanding and Exercisable (Detail)        HTML     66K 
76: R62         Cash Proceeds Along with Fair Value Disclosures     HTML     36K 
                Related to Grants, Exercises, and Vesting Options                
                (Detail)                                                         
77: R63         Summary of Unvested Restricted Stock Units          HTML     37K 
                (Detail)                                                         
78: R64         Segment Information - Additional Information        HTML     38K 
                (Detail)                                                         
79: R65         Summary of Long-Lived Assets by Geographic          HTML     33K 
                Location (Detail)                                                
80: R66         Concentrations - Summary of Net Revenue from        HTML     52K 
                Various Products (Detail)                                        
81: R67         Concentrations - Additional Information (Detail)    HTML     33K 
82: R68         Subsequent Events (unaudited) - Additional          HTML     63K 
                Information (Detail)                                             
83: R69         Consolidated Valuation and Qualifying Accounts and  HTML     39K 
                Reserves (Detail)                                                
85: XML         IDEA XML File -- Filing Summary                      XML    152K 
84: EXCEL       IDEA Workbook of Financial Reports                  XLSX    114K 
 9: EX-101.INS  XBRL Instance -- biol-20181231                       XML   4.07M 
11: EX-101.CAL  XBRL Calculations -- biol-20181231_cal               XML    226K 
12: EX-101.DEF  XBRL Definitions -- biol-20181231_def                XML    707K 
13: EX-101.LAB  XBRL Labels -- biol-20181231_lab                     XML   1.72M 
14: EX-101.PRE  XBRL Presentations -- biol-20181231_pre              XML   1.23M 
10: EX-101.SCH  XBRL Schema -- biol-20181231                         XSD    257K 
86: ZIP         XBRL Zipped Folder -- 0001564590-19-006918-xbrl      Zip    248K 


‘EX-31.2’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C: 

 

Exhibit 31.2

CERTIFICATION

I, John R. Beaver, certify that:

1.

I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2018 of BIOLASE, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 8, 2019

By:

/s/ JOHN R. BEAVER

 

 

John R. Beaver

 

 

Executive Vice President and Chief Financial Officer

(Principal Financial Officer and Principal Accounting

Officer)

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/8/19
For Period end:12/31/18SD
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/29/22  Biolase, Inc.                     424B5                  1:399K                                   Donnelley … Solutions/FA
 3/31/21  Biolase, Inc.                     10-K       12/31/20   88:15M                                    ActiveDisclosure/FA
 2/09/21  Biolase, Inc.                     424B5                  1:495K                                   Donnelley … Solutions/FA
12/08/20  Biolase, Inc.                     S-1/A                  3:585K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001564590-19-006918   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 9:11:30.1am ET